Using Tranexamic Acid to Prevent Bleeding in Blood Cancer Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness and safety of tranexamic acid (TXA) in preventing bleeding complications in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). It is a multicenter, randomized controlled trial where participants will be divided into two groups: one receiving TXA and the other receiving a placebo. The study aims to assess whether TXA can reduce the frequency and severity of bleeding in these patients, who often experience severe thrombocytopenia. The trial will monitor patient outcomes in an outpatient setting, focusing on the feasibility of patient enrollment and treatment efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Master platform inclusion criteria:

1. Age ≥ 18 years
2. Diagnosis of myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasm or acute myeloid leukemia

MYELO-CAN TXA inclusion criteria:

1. Receipt of less-intensive chemotherapy (includes both frontline and relapsed/refractory setting)
2. Severe thrombocytopenia (platelets ≤ 30x10\^9/L or platelets ≤ 50x10\^9/L prior to chemotherapy initiation)

Exclusion Criteria:

Master platform exclusion criteria:

1. Participant is deemed unlikely to survive \>30 days (as determined by clinical team)
2. Participant unable to provide informed consent

MYELO-CAN TXA exclusion criteria:

1. Known allergy to tranexamic acid
2. Active thromboembolic disease
3. Active ischemic heart disease
4. Gross hematuria
5. Stage V chronic kidney disease
6. Clinically suspected disseminated intravascular coagulation (DIC)
7. Pregnancy and/or breastfeeding

Where it's running

• CancerCare Manitoba
  Winnipeg, Manitoba, Canada Recruiting

Study contacts

• Study coordinator: Brett Houston, MD, PhD
• Email: bhouston@cancercare.mb.ca
• Phone: 204-787-8552

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CD33-armed immune cell treatment for adults with MRD-positive AML or MDS

  This treatment will try giving adults with MRD-positive AML or MDS infusions of their own T cells coated with a CD33-directed bispecific antibody together with standard hypomethylating therapy (and possibly venetoclax) to see if it is safe and lowers residual disease.

  Recruiting Phase 1 University of Virginia · Charlottesville, Virginia · NCT07270978

• Telehealth program for advance care planning in older adults with myeloid malignancies

  This study tests if a telehealth program that helps older adults with blood cancers talk about their serious illness and make healthcare plans can reduce their anxiety and improve communication with doctors.

  Recruiting University of Rochester · Rochester, New York · NCT05875805

• Evaluating BGB-11417 for treating myeloid malignancies

  This study is testing a new drug called BGB-11417, alone and with another medication, to see if it can safely help people with acute myeloid leukemia and myelodysplastic syndromes.

  Recruiting at 42 sites Phase 1/2 BeOne Medicines · Duarte, California and 46 other locations · NCT04771130

• Using hyperbaric oxygen therapy with stem cell transplants

  This study is testing whether hyperbaric oxygen therapy can help patients with chronic leukemias and myelofibrosis who are getting stem cell transplants feel better and recover more effectively.

  Recruiting Early Phase 1 University of Rochester · Rochester, New York · NCT03964506

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.